Lipid peroxidation in diabetes mellitus.

There is considerable evidence that hyperglycemia represents the main cause of complications of diabetes mellitus (DM), and oxidative stress resulting from increased generation of reactive oxygen species plays a crucial role in their pathogenesis. In fact, in the absence of an appropriate response from endogenous antioxidant mechanisms, the redox imbalance causes the activation of stress-sensitive intracellular signaling pathways. The latter play a key role in the development of late complications of DM, as well as in mediating insulin resistance (i.e., resistance to insulin-mediated glucose uptake by some cells) and impaired insulin secretion. This review, focused on lipid peroxidation in DM, will examine the mechanisms and clinical readouts of oxidative stress in this setting, the relationship between lipid peroxidation and antioxidant status in type 1 and type 2 DM, the effects of hyperglycemia and metabolic control on in vivo markers of lipid peroxidation (i.e., isoprostanes), and the association between isoprostane formation and platelet activation. Finally, possible targets of antioxidant therapy for diabetic vascular complications will be discussed.

[1]  A. Ceriello,et al.  Role of hyperglycemia in nitrotyrosine postprandial generation. , 2002, Diabetes care.

[2]  G. Davı̀,et al.  In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. , 1999, Circulation.

[3]  H. Keen,et al.  Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. , 1985, The New England journal of medicine.

[4]  G. Lutty,et al.  Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. , 1998, Free radical biology & medicine.

[5]  M. Sampson,et al.  Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. , 2002, Diabetes care.

[6]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[7]  B. Kemp,et al.  Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. , 2003, Diabetes.

[8]  R. de Caterina,et al.  Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F2-Isoprostane Formation in Hypercholesterolemic Subjects: No Further Effect of Vitamin E , 2002, Circulation.

[9]  F. Cipollone,et al.  Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. , 2000, Cardiovascular research.

[10]  M. Brownlee,et al.  Negative consequences of glycation. , 2000, Metabolism: clinical and experimental.

[11]  G. Zimmerman,et al.  Peroxisome Proliferators Enhance Cyclooxygenase-2 Expression in Epithelial Cells* , 1999, The Journal of Biological Chemistry.

[12]  E. Falleti,et al.  Total Radical-Trapping Antioxidant Parameter in NIDDM Patients , 1997, Diabetes Care.

[13]  M. Laakso,et al.  Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.

[14]  G. FitzGerald,et al.  Local Amplification of Platelet Function by 8-Epi Prostaglandin F2α Is Not Mediated by Thromboxane Receptor Isoforms* , 1996, The Journal of Biological Chemistry.

[15]  A. Roussin,et al.  Lack of concordance between plasma markers of cardiovascular risk and intima‐media thickness in patients with type 2 diabetes , 2004, Diabetes, obesity & metabolism.

[16]  T. Nicotera,et al.  Oxidative damage to DNA in diabetes mellitus , 1996, The Lancet.

[17]  A. Gotto Lipid management in diabetic patients: lessons from prevention trials. , 2002, The American journal of medicine.

[18]  E. Feldman Oxidative stress and diabetic neuropathy: a new understanding of an old problem. , 2003, The Journal of clinical investigation.

[19]  S. Wolff,et al.  Protein glycation and oxidative stress in diabetes mellitus and ageing. , 1991, Free radical biology & medicine.

[20]  A. Ceriello New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. , 2003, Diabetes care.

[21]  M. Brownlee Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.

[22]  J. Keaney,et al.  Are ACE inhibitors a "magic bullet" against oxidative stress? , 2001, Circulation.

[23]  J. Morrow,et al.  F(2)-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes. , 2000, Kidney international.

[24]  T. Lüscher,et al.  High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. , 1997, Circulation.

[25]  B. Buckley,et al.  Statins do more than just lower cholesterol , 1996, The Lancet.

[26]  G. Davı̀,et al.  Oxidative Stress and Platelet Activation in Homozygous Homocystinuria , 2001, Circulation.

[27]  B. Shilton,et al.  Role of fructose in glycation and cross-linking of proteins. , 1988, Biochemistry.

[28]  Robert M. Anderson,et al.  5. Prevention or Delay of Type 2 Diabetes , 2016, Diabetes Care.

[29]  K. Pritchard,et al.  Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Tyagi,et al.  Induction of oxidative stress by homocyst(e)ine impairs endothelial function * , 2001, Journal of cellular biochemistry.

[31]  J P Cooke,et al.  The endothelium: a new target for therapy , 2000, Vascular medicine.

[32]  Robert M. Anderson,et al.  Prevention or delay of type 2 diabetes. , 2004, Diabetes care.

[33]  J. Watkins,et al.  Diabetes, oxidative stress, and antioxidants: A review , 2003, Journal of biochemical and molecular toxicology.

[34]  K. Shirai,et al.  [Relationship between insulin resistance and oxidative stress in vivo]. , 2003, Journal of cardiology.

[35]  Emma A. Meagherx Treatment of atherosclerosis in the new millennium: is there a role for vitamin E? , 2003 .

[36]  L. Geiss,et al.  Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. , 2003, Diabetes care.

[37]  P. Low,et al.  Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. , 2003, Diabetes.

[38]  Joseph L Evans,et al.  Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. , 2002, Endocrine reviews.

[39]  U. Laufs,et al.  Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[40]  J. Olzmann,et al.  High glucose‐induced oxidative stress and mitochondrial dysfunction in neurons , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  H. Itoh,et al.  Endothelial nitric oxide synthase gene is positively associated with essential hypertension. , 1998, Hypertension.

[42]  C. Kilo,et al.  The role of cytosolic reductive stress in oxidant formation and diabetic complications. , 1999, Diabetes research and clinical practice.

[43]  S. Apfel Neurotrophic Factors and Diabetic Peripheral Neuropathy , 1999, European Neurology.

[44]  A. Carrascosa,et al.  Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. , 2003, Free radical biology & medicine.

[45]  S. Yusuf,et al.  Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. , 2002, Diabetes care.

[46]  M. Levine,et al.  A new recommended dietary allowance of vitamin C for healthy young women , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Hobbs,et al.  Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[48]  G. Davı̀,et al.  Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus , 2003, Journal of thrombosis and haemostasis : JTH.

[49]  L. Ruilope,et al.  Renoprotection and renin-angiotensin system blockade in diabetes mellitus. , 1997, American journal of hypertension.

[50]  H. Westerhoff,et al.  Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? , 2000, Atherosclerosis.

[51]  D. Betteridge,et al.  Plasma 8‐epi‐PGF2α levels are elevated in individuals with non‐insulin dependent diabetes mellitus , 1995, FEBS letters.

[52]  L S Geiss,et al.  Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. , 2001, Diabetes care.

[53]  A. Coats MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[54]  A. Flyvbjerg Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease , 2000, Diabetologia.

[55]  Jian Zhang,et al.  Hydrogen Peroxide Activates NFκB and the Interleukin-6 Promoter Through NFκB-Inducing Kinase , 2001 .

[56]  C. Soto,et al.  Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis , 2000, Nature Network Boston.

[57]  L. Tavazzi,et al.  Antioxidant vitamins and prevention of cardiovascular disease: Epidemiological and clinical trial data , 2001, Lipids.

[58]  M. Carrier,et al.  Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism , 2001, Diabetologia.

[59]  D. Dixon,et al.  Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis , 2001, The Journal of cell biology.

[60]  G. Davı̀,et al.  Thromboxane biosynthesis and platelet function in type II diabetes mellitus. , 1990, The New England journal of medicine.

[61]  G. Davı̀,et al.  Platelet activation in obese women: role of inflammation and oxidant stress. , 2002, JAMA.

[62]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[63]  A. Koller,et al.  PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes , 2004 .

[64]  D. O'Connor,et al.  Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk , 2000, Journal of hypertension.

[65]  M. Penn,et al.  Lipoprotein Oxidation and Lipoprotein-lnduced Cell Injury in Diabetes , 1992, Diabetes.

[66]  J. Loscalzo,et al.  Diabetes, oxidative stress, and platelet activation. , 1999, Circulation.

[67]  L. Aiello,et al.  Role of vascular endothelial growth factor in diabetic vascular complications. , 2000, Kidney international. Supplement.

[68]  B. Halliwell,et al.  Reoxygenation injury and antioxidant protection: a tale of two paradoxes. , 1990, Archives of biochemistry and biophysics.

[69]  S. Yagihashi,et al.  Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients , 2002, Diabetologia.

[70]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[71]  P. Tsao,et al.  Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. , 2001, Circulation research.

[72]  R. Stocker,et al.  The use of antioxidant supplements in coronary heart disease. , 2002, Atherosclerosis.

[73]  I. Hirsch,et al.  Reduced Plasma Peroxyl Radical Trapping Capacity and Increased Susceptibility of LDL to Oxidation In Poorly Controlled IDDM , 1994, Diabetes.

[74]  S. Devaraj,et al.  Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. , 2001, Clinical chemistry.

[75]  G. Davı̀,et al.  Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. , 1997, Circulation.

[76]  U. Bayraktutan,et al.  Free radicals, diabetes and endothelial dysfunction , 2002, Diabetes, obesity & metabolism.

[77]  F. Santilli,et al.  Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus: Role of Interleukin-6 and Disease Duration , 2003, Circulation.

[78]  G. Davı̀,et al.  In Vivo Formation of 8-Epi-Prostaglandin F2α Is Increased in Hypercholesterolemia , 1997 .

[79]  R. Mccarty,et al.  Glycemic control of pain threshold in diabetic and control rats , 1990, Physiology & Behavior.

[80]  J. Morrow,et al.  The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. , 1992, Prostaglandins.

[81]  S. Kahn,et al.  Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. , 1999, Diabetes.

[82]  M. Roncaglioni,et al.  Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. , 2003, Diabetes care.

[83]  Tonutti,et al.  Antioxidant defences are reduced during the oral glucose tolerance test in normal and non‐insulin‐dependent diabetic subjects , 1998, European journal of clinical investigation.

[84]  J. Williamson,et al.  Glucose and diabetic vascular disease 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[85]  E. Anggard,et al.  F2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: effects of vitamin E. , 1999, European journal of pharmacology.

[86]  Kathleen M. Fairfield,et al.  Vitamins for chronic disease prevention in adults: scientific review. , 2002, JAMA.

[87]  D. Sorescu,et al.  NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.

[88]  S. Robins Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? , 2003, Current opinion in lipidology.

[89]  G. FitzGerald,et al.  Oxidative stress and platelet activation in diabetes mellitus. , 1996, Diabetes research and clinical practice.